Literature DB >> 20733313

Treatment and management of psoriasis with nail involvement: a focus on biologic therapy.

Richard G Langley1, Esteban Daudén.   

Abstract

Nail involvement in psoriasis is typically overlooked, although it can affect up to 50% of patients with psoriasis and cause functional impact as well as psychological stress that can significantly affect quality of life. In addition, psoriatic patients with nail disease tend to have a more severe skin condition, a higher rate of unremitting and progressive arthritis and more associated anxiety and depression. Historically, the treatment of nail psoriasis has proven difficult, with most patients feeling that the treatment for their nail disease was unsatisfactory. The current management of nail psoriasis includes topical, intralesional and systemic therapies, although little clinical evidence is available on the effectiveness of conventional treatments and, consequently, no specific treatment approach has been fully supported. Biologic agents are beginning to emerge as a viable option to treat patients with both cutaneous and nail clinical manifestations of psoriasis and psoriatic arthritis. The extra disease burden that nail symptoms place on the patient can be considered indicative of a more severe form of the disease and should be taken into consideration when assessing treatment options. Copyright (c) 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20733313     DOI: 10.1159/000316179

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  11 in total

1.  Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.

Authors:  Arthur Kavanaugh; Philip Helliwell; Christopher T Ritchlin
Journal:  Rheumatol Ther       Date:  2016-02-29

2.  Role of HLA-DR Alleles to Increase Genetic Susceptibility to Onychomycosis in Nail Psoriasis.

Authors:  Hilda Carrillo-Meléndrez; Esteban Ortega-Hernández; Julio Granados; Sara Arroyo; Rodrigo Barquera; Roberto Arenas
Journal:  Skin Appendage Disord       Date:  2016-05-13

Review 3.  Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

4.  Racial, Ethnic, and Sex Disparities in Nail Psoriasis Clinical Trials: A Systematic Review.

Authors:  Jose W Ricardo; Yuqing Qiu; Shari R Lipner
Journal:  Skin Appendage Disord       Date:  2022-01-14

Review 5.  Small Molecules and Biologics in the Treatment of Nail Psoriasis.

Authors:  Dimitrios Rigopoulos; Anna Stathopoulou; Stamatios Gregoriou
Journal:  Skin Appendage Disord       Date:  2020-04-30

6.  Serum levels of TNF- α , IL-12/23 p40, and IL-17 in psoriatic patients with and without nail psoriasis: a cross-sectional study.

Authors:  Aikaterini Kyriakou; Aikaterini Patsatsi; Timoleon-Achilleas Vyzantiadis; Dimitrios Sotiriadis
Journal:  ScientificWorldJournal       Date:  2014-12-31

Review 7.  New insight into the pathogenesis of nail psoriasis and overview of treatment strategies.

Authors:  Alessandra Ventura; Mauro Mazzeo; Roberta Gaziano; Marco Galluzzo; Luca Bianchi; Elena Campione
Journal:  Drug Des Devel Ther       Date:  2017-08-30       Impact factor: 4.162

Review 8.  Challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of disease.

Authors:  Trinh Hermanns-Lê; Enzo Berardesca; Gérald E Piérard; Marianne Lesuisse; Claudine Piérard-Franchimont
Journal:  J Biomed Biotechnol       Date:  2012-08-13

9.  Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy.

Authors:  Georgios Kokolakis; Frank Bachmann; Kerstin Wolk; Robert Sabat; Sandra Philipp
Journal:  Acta Derm Venereol       Date:  2020-07-28       Impact factor: 3.875

Review 10.  Nail psoriasis: the journey so far.

Authors:  Alka Dogra; Amanjot Kaur Arora
Journal:  Indian J Dermatol       Date:  2014-07       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.